'Hiv 1 rna 50' presentation slideshows

HIV Update Ardis Moe, M.D. amoe@mednet.ucla UCLA CARE clinic/NEVHC Van Nuys 21 June 2014

HIV Update Ardis Moe, M.D. amoe@mednet.ucla.edu UCLA CARE clinic/NEVHC Van Nuys 21 June 2014. I do not have any financial arrangements or affiliations with commercial sponsors which have direct interest in the subject matter. Goals:. Discuss PREP and PEP options DHHS treatment options

644 views • 48 slides

New Drugs and New Strategies from the 2014 CROI

New Drugs and New Strategies from the 2014 CROI. Jeffrey Lennox, MD Co-PI, Emory HIV/AIDS Clinical Trials Unit. Learning Objectives. After attending this presentation, learners will be able to:. Describe the antiviral properties of 4 new medications in clinical trials

593 views • 45 slides

New Drugs and New Strategies from the 2014 CROI

New Drugs and New Strategies from the 2014 CROI. Jeffrey Lennox, MD Co-PI, Emory HIV/AIDS Clinical Trials Unit. Learning Objectives. After attending this presentation, learners will be able to:. Describe the antiviral properties of 4 new medications in clinical trials

549 views • 45 slides

Conference Call Line: 1-800 -920-7487 Participant Code: 9982883

Conference Call Line: 1-800 -920-7487 Participant Code: 9982883 Please type your name into the chat box to confirm your attendance. Visit us at www.med.unc.edu / ncaidstraining.

385 views • 38 slides

Thinking of Now and Tomorrow: Emerging Treatment Paradigms

Thinking of Now and Tomorrow: Emerging Treatment Paradigms. Pedro Cahn. Disclosures. Advisory boards : Merck, ViiV Healthcare Research funds : Abbvie , Merck, Richmond, ViiV Healthcare Speaker at educational activities : Abbvie , Gilead, Merck, ViiV Healthcare.

506 views • 32 slides

Disclosures and Acknowledgments

Longer-term (96-week) Efficacy and Safety of Switching to Bictegravir, Emtricitabine and Tenofovir Alafenamide (B/F/TAF) in Women.

222 views • 22 slides

a ?10% non-inferiority margin for individual studies.

527 views • 13 slides

Switch to LPV/r monotherapy

Switch to LPV/r monotherapy. Pilot LPV/r M03-613 LPV/r Mono KalMo OK OK04 KALESOLO MOST HIV-NAT 077. OK Study: Switch LPV/r + 2NRTIs to LPV/r monotherapy. Design. Randomisation 1 : 1 Open-label. W48. N = 21. 42 HIV+ ? 18 years On 2 NRTIs + LPV/r > 4 weeks

53 views • 5 slides

Switch to ATV/r monotherapy - ATARITMO - Swedish Study - ACTG A5201 - OREY

Switch to ATV/r monotherapy - ATARITMO - Swedish Study - ACTG A5201 - OREY. ATARITMO Study: Switch to ATV/r monotherapy. Design. Open-label Single-arm Pilot trial. W24. HIV+ Conventional HAART > 6 months (stable during last 3 months) Or IDV/r monotherapy

163 views • 3 slides